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MicrosensorThe inﬂuence of P-glycoprotein (ABCB1) in drug resistance as well as drug absorption and disposition is an
important factor to be considered during the development of new drugs. Thus, the early identiﬁcation and
exclusion of compounds showing a high afﬁnity towards P-glycoprotein can help to select drug candidates.
The aim of our study was to implement a label-free assay for the identiﬁcation of P-glycoprotein substrates in
living cells. For this approach, a multiparametric, chip-based sensor system was used to determine
extracellular acidiﬁcation, cell respiration and adhesion upon stimulation with P-glycoprotein substrates.
Using L-MDR1 cells, a human P-glycoprotein overexpressing cell line, the inﬂuence of P-glycoprotein
activity was determined for seven different compounds, demonstrating the applicability of the system for P-
glycoprotein substrate identiﬁcation. Effects were concentration dependent, as shown for the P-
glycoprotein substrate verapamil, and were associated with cellular acidiﬁcation and respiration. P-
glycoprotein ATPase activation by verapamil could be described by a Michaelis–Menten type kinetic proﬁle
showing saturation at high substrate concentrations. TheMichaelis–Menten constants KMwere determined
to be 0.92 μM (calculated based on extracellular acidiﬁcation) and 4.9 μM (calculated based on cellular
respiration). Control experiments using 100 nM of the P-glycoprotein inhibitor elacridar indicated that the
observed effects were related to P-glycoprotein ATPase activity. In contrast, wild-type LLC-PK1 cells not
expressing P-glycoprotein were not responsive towards stimulation with different P-glycoprotein
substrates. Summarizing these ﬁndings, the used microsensor system is a generic system suitable for the
identiﬁcation of P-glycoprotein substrates. In contrast to biochemical P-glycoprotein assays, activation of
the drug efﬂux pump can be monitored on-line in living cells to identify P-glycoprotein substrates and to
study the molecular mechanisms of adenosintriphosphate-dependent active transport.r ABCB1; P-gp, P-glycoprotein;
iﬁcation rate; OCR, oxygen
IDES, interdigitated electrode
: + 41 61 267 15 16.
r).
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ATP-binding cassette (ABC) transporters are one of the largest
families of multidomain integral membrane proteins that use the
energy of ATP hydrolysis to translocate molecules across cellular
membranes. They are found in all species including man [1]. These
efﬂux pumps recognize a wide range of chemically diverse endoge-
nous and exogenous compounds and act as gatekeepers contributing
in cellular defense [2,3]. They are involved in biomedical phenomena
like multidrug-resistance of cancer cells or poor bioavailabilityof drugs [4]. One of the best characterized ABC transporters is
P-glycoprotein (P-gp), the gene product of the human multi-drug
resistance (MDR1) gene and the ﬁrst member of subfamily B of the ABC
transporters (ABCB1). P-gp is highly expressed in human tissues with
protective function and is found on the luminal surface of cellular
barriers including the kidney proximal tubule, small intestine and colon,
testis, adrenal cortex and the blood–brain barrier [5]. The expression
pattern of P-gp suggests a protective function of P-gp towards
potentially toxic xenobiotics. P-gp is a 170 kDa protein consisting of
two homologous drug binding transmembrane domains [6] and a
cytosolic nucleotide-binding domain with ATPase activity [7]. P-gp has
broad substrate speciﬁcity and signiﬁcantly modulates the pharmaco-
kinetics of many chemically unrelated drugs [8]. As a consequence,
efﬁcient screening methods are needed to identify substrates or
inhibitors of P-gp during the drug discovery and development process
[9]. For the identiﬁcation of P-gp inhibitors, high-throughput ﬂuores-
cent assays exist such as the rhodamine123 [10] or the calcein–AM [11]
assay. However, identiﬁcation of substrates of P-gp remains a challenge:
Fig. 1. Photographic representation of the Bionas chip-based sensor system. The silicon
sensor chip has a surface area of 74 mm2. Integrated sensors include one IDES for the
measurement of cellular impedance, ﬁve ISFET sensors for the measurement of pH and
ﬁve Clark-type oxygen sensors (picture reproduced with permission of Bionas Ltd.).
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any in vivo experimentation relies on sensitive, compound-speciﬁc and
expensive analytical procedures such as the use of radiolabeled test
compounds or quantitative mass spectroscopy. In contrast, generic
biochemical assays such as the ATPase release assay [13] make use of
membrane preparations of P-gp. However, these assays are not
necessarily representative for the in vivo situation since membrane
integrity is disturbed and the orientation of P-gp binding sites towards
the intracellular or extracellular space is lost during the preparation of
cell homogenates. It should be noted that for living cells, a label-free and
real-timemethodwas introduced recently, which is based on single cell
monitoring of drug-related ﬂuorescence [14].
In view of these limitations, the aim of our studywas to implement
a new label-free method to identify P-gp substrates on-line in living
cells and to validate this assay as a generic tool for the reliable
identiﬁcation of P-gp substrates. Regeneration of the consumed ATP
via glycolysis is coupled to the formation of carbon dioxide and lactate
which are released into the extracellular milieu as carbonic acid and
lactic acid [15]. Besides acidiﬁcation, oxygen is consumed during
glycolysis resulting in a decrease of oxygen concentration in the
extracellular environment. These two processes, i.e. oxygen con-
sumption and extracellular acidiﬁcation, are indicators for ATP
regeneration, and thus, P-gp activity. Using a microsensor system, a
label-free and real-time analyzing system for the identiﬁcation of P-gp
substrates in living cells was established.
2. Materials and methods
2.1. Compounds
Colchicine was from Biochrom AG (Berlin, Germany) and elacridar
was obtained from LGM Pharma (Boca Raton, Florida, USA). All other
chemicals were purchased from Sigma (Buchs, Switzerland). Ten
millimolar stock solutions were prepared using DMSO. The DMSO
concentrations in the ﬁnal solutions did not exceed 0.1% (v/v).
2.2. Cell culture
The human P-gp overexpressing cell line L-MDR1 derived from the
porcine kidney epithelial cell line LLC-PK1 was obtained under license
from professor Alfred Schinkel, The Netherlands Cancer Institute
(Amsterdam, The Netherlands). Cells were maintained under stan-
dard cell culture conditions as described previously [8,9]. In brief, cells
were cultivated at passage numbers 12–26 in 75 cm2 cell culture
ﬂasks at 37 °C in medium 199 with GlutaMAX (Gibco/Invitrogen,
Basel, Switzerland) supplemented with 50 IU/mL penicillin, 50 μg/mL
streptomycin and 10% (v/v) fetal bovine serum (PAA Laboratories,
Pasching, Austria) in a humidiﬁed atmosphere containing 5% CO2.
L-MDR1 cells were subcultured in the presence of 150 ng/mL
colchicine to maintain P-gp expression levels. Colchicine was omitted
from medium 12 h prior to use in the experiments to avoid the
development of other drug resistance mechanisms that could modify
the action of P-gp [16]. Once in culture and induced, cells have been
shown to express constant levels of P-gp for up to 15 passages [17].
2.3. Microsensor experiments
Cells were detached by trypsination (Invitrogen) and analyzed by
a Vi-cell XR cell viability analyzer (Beckman Coulter, Krefeld,
Germany). Cells were then diluted in culture medium to reach a
ﬁnal concentration of 2.9×105 cells per milliliter medium and a
0.35 mL aliquot of this cell suspension was transferred to a pre-
warmed metabolic chip and incubated for at least 16 h prior to use. A
Bionas® 1500 microsensor system (Bionas, Rostock, Germany) was
used to continuously record cellular physiological parameters. The
system was used as described previously [18]. The core of the systemconsists of a silicon sensor chip SC1000 (Fig. 1) containing ISFET and
Clark-type sensors for the measurement of dynamic changes of
acidiﬁcation and oxygen consumption.
Cell adhesion is monitored by means of impedance measurements
using an IDES electronic circuit. The height of the reaction chamber
above the sensor surface is 200 μm. Cells were seeded directly onto
the silicon chip without prior surface treatment or coating to ensure
optimal signal detection. During the experiment, assay medium (see
below)was delivered to the cells at a constant ﬂow rate of 250 μL/min.
The supply of assay medium was interrupted periodically. This stop/
go cycles (Fig. 2) were carried out during the whole experiment.
Typically, the stop and pump phases lasted 2 min each. During these
“stop phases,”metabolic breakdown products of the cells (lactate and
carbonate) were released into the assay medium and were allowed to
accumulate resulting in a change of extracellular pH [15]. Extracellular
oxygen concentrations were monitored in parallel. Enhanced meta-
bolic activity of cells requires increased oxygen consumption for
regeneration of energy, which is detectable during the stop phases by
a decrease of the oxygen concentration. Initial rates of extracellular
acidiﬁcation and respiration were calculated by changes of the slope
in the stop phases and a linear regression analysis. Rates were
standardized to 100% of baseline signal just before compound
treatment. Impedance measurements were carried out continuously
to monitor cell adhesion, and thus, cell viability and conﬂuence [19].
As a control, 0.2% Triton X-100 was added to the cells at the end of
each experiment to induce cell membrane destruction, and thus,
detachment of cells from the surface of the sensor chip. By this control,
at the end of the experiment, a reference signal of the cell-free sensor
surface was obtained (0% control value) [19]. It should be noted that
pH values and oxygen concentrations are determined with respect to
corresponding reference values. These relative signals are related to a
0% control value of an empty sensor chip and to a 100% reference
value representing the baseline signal of a cell coated chip prior to
compound treatment.
2.4. System initialization
Prior to each experiment, the supply lines of the system were
conditioned in a three-step procedure: disinfection with 70% (v/v)
aqueous ethanol, ﬂushingwith an excess of phosphate-buffered saline
(PBS) and rinsing with low buffered assay medium. For the
measurements, an assay medium with low buffer capacity was
required. The assay medium was prepared from a 10× concentrated
Fig. 2. Representative example of a microsensor experiment. Cellular respiration of L-
MDR1 cells is shown during several 2 min stop (pump off) and 2 min go (pump on)
cycles (solid lines). Recorded data (square symbols) are plotted against time and
include measurement of extracellular acidiﬁcation (A) and oxygen concentration (B).
The pH is proportional to a measured voltage (U) and the oxygen concentration is
proportional to a measured current (I). Extracellular acidiﬁcation (A) and cellular
respiration (B) rates were calculated from the initial slope of each stop phase by a linear
regression.
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MAX, 2% (v/v) fetal bovine serum, 50 IU/mL penicillin and 50 μg/mL
streptomycin. The assaymedium did not contain NaHCO3. To preserve
the osmotic balance of the buffer system, a ﬁnal concentration of
26.2 mM NaCl was used. The medium was adjusted to pH 7.4. Before
use, the integrity of the cell-monolayer covering the surface of the
microsensor chip was veriﬁed using a Motic DM-39C reﬂected-light
microscope (Motic Group Ltd., Hong Kong, China). Cell monolayers
with a cellular conﬂuence below 80% were rejected for use.
2.5. Measurement
Signals from the microsensor chip were recorded after a
stabilization phase of at least 4 h. The duration of the stabilization
phase was variable and was dependent on the baseline metabolic
activity of the cells. Experiments were initiated as soon as a constant
baseline signal to noise ratio from the different sensors could be
acquired. During 5 go cycles, cells were exposed to different test
substances in concentration ranges between 0.1 and 10 μM dissolved
in assay medium.
Raw data were recorded by all sensors in intervals of 10 s to obtain
12 raw data points per stop and go cycle (Fig. 2). From these data
points, initial rates of acidiﬁcation and cellular respiration were
derived by linear regression. Stimulation phases with test substances
were followed by a wash-out phase of at least 2 h before a new
stimulation phase was initiated. These extended wash-out cycles
were required to allow for a regeneration of the cells and a complete
wash-out of the test substances. After the experiment, impedancevalues were recorded following solubilization of cells by 0.2% (v/v)
Triton X-100. This control is used to compare cell monolayer integrity
during the experiment with a reference value obtained from a cell-
free sensor chip at the end of the experiment. This value represents by
deﬁnition the 0% reference control value (see above).
2.6. Statistics
A two-tailed Mann–Whitney U test was used to compare
metabolic rate points before and during compound treatment. The
level of statistical signiﬁcance was deﬁned as pb0.05. The statistical
calculation of the Mann–Whitney U test was performed using
GraphPad Prism software (Version 5.03, GraphPad Software Inc., La
Jolla, CA, USA). Each experiment was performed at least in triplicates.
Results are expressed as the mean±SEM, where SEM is the standard
error of the mean.
3. Results and discussion
In the present study, a multiparametric, chip-based sensor system
(Fig. 1) was used for real-time identiﬁcation of P-glycoprotein (P-gp)
substrates in human P-gp overexpressing LLC-PK1 cells (L-MDR1).
The used microsensor system is an analytical tool for on-line
monitoring of changes in extracellular acidiﬁcation rate (ECAR), cell
respiration (oxygen consumption rate—OCR) and cell adhesion
(Fig. 2). The results obtained with P-gp overexpressing L-MDR1
cells were compared with those of wild-type LLC-PK1 cells exhibiting
only a marginal P-gp expression [20]. Seven marketed drugs, known
to be substrates or non-substrates of P-gp, were used as reference
compounds for system validation: caffeine and propranolol are not
substrates of P-pg whereas verapamil, daunorubicin, fexofenadine,
quinidine and loperamide are known substrates of the transporter. In
contrast to previous studies in which pH microsensors were used for
mechanistic studies on P-gp ATPase activation [21], our experiments
included measurements of cellular oxygen consumption and cell
adhesion and were focused on efﬁcient identiﬁcation of P-gp
substrates.
The microsensor assay was optimized with respect to maximal
stimulation amplitudes to allow for a sensitive and reliable recording
of signals. Important assay parameters included the use of an assay
mediumwith a low buffer capacity supplemented with 2% (w/v) fetal
bovine serum albumin. Serum proteins reduce unspeciﬁc binding of
test compounds to surfaces such as the plastic tubings of the
microsensor instrument and enhance cellular viability in the assay
system during incubation times of up to 24 h. Optimal cell densities
were in a range of 0.75 to 1.5×104 attached cells per chip. The design
of the actual incubation chamber (i.e. the volume of the 200 μm space
between the surface of the sensor chip and the chamber lid) is of
critical importance. In our experimental set-up, the effective volume
of the incubation chamber was 5.6 μL. Such a minimal volume is
needed tomonitor the rate of accumulation of metabolic products and
depletion of oxygen in the assay medium. A further reduction of the
incubation chamber volume led to system instability and a high
signal-to-noise ratio of the measured signal. During measurements,
the ﬂow of assaymediumwas periodically interrupted for 2 min. After
each measuring period, the incubation chamber was ﬂushed for
another 2 min with assay medium before a new measuring cycle was
initiated. Prolonged phases of reduced ﬂow of assay medium should
be avoided due to detrimental effects on cell viability and overall
system stability. Viability of cells was monitored continuously by
measurements of cellular impedance. Deviations in the range of less
than ±15% from initial values over a run time of 1500 min were
considered to be acceptable and were attributed to cell proliferation
or small morphological changes after compound treatment, i.e.
shrinking or swelling. Experiments were discontinued as soon as a
change in impedance in excess of these limits was recorded.
Fig. 4. Stimulation of P-gp in the presence of different concentrations of verapamil.
Extracellular acidiﬁcation (ECAR, circles) and oxygen consumption (OCR, triangles) in
P-gp overexpressing L-MDR1 cells (solid symbols) and wild-type LLC-PK1 (open
symbols) cells measured as a function of increasing concentrations of verapamil. Solid
lines: curve ﬁtting using a Michaelis–Menten type kinetics model. Signals obtained at
verapamil concentration of 50 μM were rejected for kinetic calculations. Level of
signiﬁcance between L-MDR1 and LLC-PK1 controls: pb0.001, n=4.
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presence of verapamil (a P-gp substrate [9,22]) and the negative
control caffeine [23]. Experiments were initiated as soon as a stable
baseline metabolic rate was attained (100% threshold in Fig. 3). ECAR
as well as OCR could be identiﬁed to correlate with P-gp activation
(Fig. 3, phase 1 of the experiment). Selectivity of the observed P-gp
stimulatory effects were demonstrated by inhibition of P-gp activity
with elacridar (GF120918), a selective third-generation P-gp inhibitor
[24,25] (Fig. 3, phase 3). Elacridar on its own does not stimulate P-gp
ATPase activity but has a slight inhibitory effect on overall metabolic
activity of L-MDR1 cells (Fig. 3, phase 2). At the end of the experiment
(Fig. 3, phase 4), reference 0% signal-levels of the microsensor chip
were determined by Triton X-100-mediated removal of attached cells.
Observed acidiﬁcation rates and respiration rates increased in the
presence of increasing concentrations of up to 15 μM verapamil
(Fig. 4, black symbols) and followed Michaelis–Menten type kinetics.
Stimulation of P-gp by verapamil showed saturation at high
concentrations and was characterized by a KM value of 0.92±
0.12 μM (calculated based on ECAR, mean±SEM, n=4) and 4.9±
2.7 μM (calculated based on OCR, mean±SEM, n=4). These values
are in good agreement with a KM value of 1.5 μM reported previously
[26] for the stimulation of P-gp by verapamil at low substrate
concentrations. It is important to note that for the ﬁrst time (to our
knowledge) P-gp activation was monitored not only by extracellular
acidiﬁcation [26] but also by stimulation of cellular respiration. In our
experimental setup, ECAR deliver stronger and more reliable signals
as compared to OCR: Vmax values for ECAR (57.4±1.6% as compared
to 0% control, mean±SEM, n=4) were twice as high as the
corresponding Vmax values for OCR (25.4±5.2% as compared to 0%
control, mean±SEM, n=4). At substrate concentrations of 50 μM
verapamil, a sudden drop in ECAR as well as in OCR was observed and
could be attributed to either cellular toxicity or substrate inhibition at
high concentrations [21] of the test compound (Fig. 4). However, for
none of the tested verapamil concentrations, cell impedance deviated
from 100% control values by more than ±13%. In a separate set of
control experiments (Fig. 4, open symbols), P-gp-deﬁcient LLC-PK1
cells were incubated in the presence of verapamil and did not show
any stimulation effects in either ECAR or OCR. Again, high concentra-
tions of verapamil (50 μM) seemed to inhibit cellular metabolic
activity.
The question arises, whether ECAR or OCR should be used to
monitor P-gp activation. Both parameters can be used to monitor
cellular responses upon stimulation of cells using P-gp substrates and
are therefore correlated. ECAR is predominantly linked to glycolysisFig. 3. Stimulation of P-gp overexpressing L-MDR1 cells in the presence and absence of
the P-gp inhibitor elacridar. Phase 1: stimulation of L-MDR1 cells with 10 μMverapamil
results in extracellular acidiﬁcation (ECAR, ○) and increased oxygen consumption rate
(OCR, ▼). Phase 2: addition of 100 nM elacridar after a wash-out phase. Phase 3:
addition of 10 μM verapamil in the presence of 100 nM elacridar. Phase 4: Triton X-100
(0.2%, v/v) treatment at the end of the experiment to obtain the 0% reference value of
the empty sensor chip.whereas OCR is indicative of mitochondrial respiration. In our
experiments (Figs. 3 and 4), extracellular acidiﬁcation was demon-
strated to deliver a three-fold higher signal than oxygen consumption.
In addition, baseline respiration rates changed over time during
prolonged experimental periods. It is tempting to speculate that
overall cellular viability and/or possibly mitochondrial toxicity might
be confounding factors inﬂuencing cellular respiration in an unpre-
dictable way. In view of the reduced sensitivity as well as the
uncertainty associated with the OCR parameter, it was decided to
quantitate P-gp stimulation based on extracellular acidiﬁcation only,
but to monitor OCR values as an additional control in parallel to
identify cell-permeating compounds affecting mitochondrial
respiration.
The chip-based sensor system was also used to identify substrates
of P-gp. Representative examples of marketed drugs are shown in
Fig. 5. Activation of P-gp was expressed as ratio between acidiﬁcation
ratesmeasured during and immediately before stimulation of L-MDR1
cells (ΔECAR). Propranolol, caffeine, quinidine, verapamil and
loperamide were used at a substrate concentration of 10 μM. TheFig. 5. Identiﬁcation of P-gp substrates using the microsensor system in combination
with P-gp overexpressing L-MDR1 cells. Extracellular acidiﬁcation rates were
determined in the presence and absence of test compound (10 μM ﬁnal substrate
concentration with the exception of 1 μM of daunorubicin and fexofenadine). Ratios
between acidiﬁcation rates before and during stimulation (ΔECAR) are shown. Data are
means±SEM, nN3. Levels of statistical signiﬁcant difference between acidiﬁcation
rates in unstimulated or stimulated cells are pb0.05 (*), p=0.01 (**) or pb0.001 (***).
Fig. 6. Control experiments demonstrating absence of stimulatory effects in wild type
LLC-PK1 cells. Caffeine (phase 1), verapamil (phase 2), loperamide (phase 3), quinidine
(phase 4) and paclitaxel (phase 5) did not induce extracellular acidiﬁcation (ECAR) in
P-gp deﬁcient LLC-PK1 cells. All compounds were tested at a substrate concentration of
10 μM. Triton X-100 (0.2%, v/v) treatment (phase 6) at the end of the experiment was
used to obtain the 0% reference value of the cell-free sensor chip.
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reduced to 1 μM to avoid cellular toxicity. Propranolol and caffeine,
which do not interact with P-gp, were used as negative controls. All P-
gp substrates were correctly identiﬁed and showed statistically
signiﬁcant differences (pb0.05) in ECAR as compared to the negative
controls. Cellular impedance, and thus, cellular viability were not
affected by the test compounds in the used concentration range.
Absence of cellular toxicity or unspeciﬁc stimulatory effects was
conﬁrmed in a set of control experiments (Fig. 6). None of our test
compounds stimulated ECAR using the P-gp-deﬁcient LLC-PK1 cell
line under the same experimental conditions.4. Conclusions
In the present study, stimulation of P-gp was monitored by the
measurement of extracellular acidiﬁcation. In addition, cellular
respiration was used for the ﬁrst time as an indicator of P-gp-related
metabolic activity. The microsensor assay was demonstrated to be a
sensitive, label-free and generic method to identify substrates of P-gp
and to determine kinetic parameters of P-gp ATPase activation such as
the Michaelis–Menten constant, KM. One sensor chip can be used for
multiple consecutive measurements. A critical factor for such
measurements is the intrinsic toxicity of test compounds, which
may lead to cellular stress, and hence, unspeciﬁc metabolic activation
of the target cell as soon as a critical substrate concentration threshold
is reached. It is therefore necessary to test different substrate
concentrations in P-gp-deﬁcient LLC-PK1 control cells prior to the
actual experiment in L-MDR1 cells. In the present study (as
demonstrated in Fig. 6), substrate concentrations of test compounds
(e.g., 1 or 10 μM) were chosen in accordance with these principles to
avoid artifacts and toxic effects. The need for time-consuming control
experiments limits the throughput of the microsensor system. A
solution to this problemmight be the use of a multiple-sensor system,
in which several test compounds can be measured in parallel in a
semi-automated and cost-efﬁcient way. Such systems may offer
additional advantages in that ABC transporters other than P-gp might
be investigated based on their ATPase activity.Conﬂict of interest statement
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